Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Viral Vector Based Gene Therapy in Patients with Hemophilia a: A Systematic Review

Wajeeha Aiman, Syeda Hafsa Kazmi, Memoona Saeed, Muhammad Imran Khan, Zainab Omar, Muhammad Suleman, Taimoor Jamil, Mahak Khadija Bhatti, Sigmone Khalid Butt, Hina Zubair, A. Supraja, Maha Zafar, Yusra Arooj, Muhammad Ashar Ali

Blood (2022) 140 (Supplement 1): 12992–12993.

https://doi.org/10.1182/blood-2022-158105

Published: 2022

Journal Articles

Efficacy and Safety of IDH Inhibitors in AML: A Systematic Review of Clinical Trials

Muhammad Ashar Ali, Shadma Fatima, Ashish Nepal, Huda Khan, Mahak Khadija Bhatti, Memoona Saeed, Rabiya Niaz, Rooma Habib, Zainab Omar, Zubair Shafique, Muhammad Imran Khan, Muhammad Hassab, Wajeeha Aiman

Blood (2022) 140 (Supplement 1): 11763–11764.

https://doi.org/10.1182/blood-2022-158821

Published: 2022

Journal Articles

Non-Hodgkin Lymphoma Mortality in the Elderly Population By Race, Gender, and Region in the United States

Yi Lee, Qasim Jehangir, Yu-Che Lee, Ronan W. Hsieh, Imran Khan, Geetha Krishnamoorthy, Anupam A Sule, Judie R Goodman

Blood (2021) 138 (Supplement 1): 2535.

https://doi.org/10.1182/blood-2021-146325

Published: 2021

Journal Articles

Role of Serial Positron Emission Tomography (PET) Scans in Indolent Lymphomas' Management - Interim Results from an Ongoing Prospective Study at King Fahd Medical City, Riyadh, Saudi Arabia

Nawal Faiez Alshehry, MD, Musab Ahmed, MD, Shahid Iq bal, MD, Atta Munawar Gill, MD, Mohammad E Dawiama, MD, Ahmed Ali Butt, MD, Belal Albtoosh, BSc, RN, Ibraheem H. Motabi, MD, Mubarak S. AlGhamdi, MD, Imran Khan Tailor, MD, Syed Altaf, MD, Syed Ziauddin A. Zaidi, FRCP, FRCPath, MBBS, Shanker Raja, MD

Blood (2018) 132 (Supplement 1): 5342.

https://doi.org/10.1182/blood-2018-99-116529

Published: 2018

Journal Articles

Phase 2 Study of 5 Days Azacytidine Priming Prior to Fludarabine, Cytarabine and G-CSF Combination for Patients with Relapsed or Refractory AML

Ibraheem H. Motabi, MD, Shahid Iqbal, MD, Syed Ziauddin A. Zaidi, FRCP, FRCPath, MBBS, Belal Albtoosh, BSc, RN, Nawal Faiez Alshehry, MD, Mubarak S. AlGhamdi, MD, Imran Khan Tailor, MD, Syed Altaf, MD

Blood (2018) 132 (Supplement 1): 5181.

https://doi.org/10.1182/blood-2018-99-114037

Published: 2018

Journal Articles

Prognostic Stratification of Acute Myeloid Leukemia and Mylodysplastic Syndrome Patients on the Basis of Genetic Variations

Muhammad ALI, MBBS, Mphil, Sulman Basit, PhD, Muhammad tariq Masood, MBBS, PhD, Yasar Mehmood Yousafzai, MBBS, PhD, Asif Naseer, MBBS, PhD, Sadeeq ur Rahman, PhD, Musharraf Jelani, PhD, Imran Khan, Msc, Yousaf Khan, MSc, Abid Jameel, MBBS, PhD, Jawad Ahmed, MBBS, PhD, Abid Sohail Taj, PhD MBBS, MRCPath

Blood (2016) 128 (22): 5239.

https://doi.org/10.1182/blood.V128.22.5239.5239

Published: 2016

Journal Articles

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Saad Z. Usmani, Brendan M. Weiss, Torben Plesner, Nizar J. Bahlis, Andrew Belch, Sagar Lonial, Henk M. Lokhorst, Peter M. Voorhees, Paul G. Richardson, Ajai Chari, A. Kate Sasser, Amy Axel, Huaibao Feng, Clarissa M. Uhlar, Jianping Wang, Imran Khan, Tahamtan Ahmadi, Hareth Nahi

Blood (2016) 128 (1): 37–44.

https://doi.org/10.1182/blood-2016-03-705210

Published: 2016

Includes: Supplemental data

Journal Articles

Outcome of Elderly Patients with Hodgkin's Disease-Single Centre Experience from Riyadh, Saudi Arabia

Imran Khan Tailor, MBBS, MD MRCP, FRCPath, Syed Ziauddin A. Zaidi, MBBS, FRCP, FCPS, FRCPath, FACP, Ibraheem H Motabi, MRCP MD, N F Alshehry, MD, Assem A Elghazaly, MBBChir, MS, MRCP, SBAH, Samer Homoud S Almudaibigh, MD SBIM, SBAH, Mubarak S. AlGhamdi, MD, Atta Munawar Gill, MBBS, MRCPI, SBAH, Shahid Iqbal, MBBS, FCPS, MRCP, G Murtaza, MBBS, FCPS, A Butt, MBBS

Blood (2015) 126 (23): 5070.

https://doi.org/10.1182/blood.V126.23.5070.5070

Published: 2015

Journal Articles

Correlation of PET Scan Negativity and Higher Absolute Lymphocytes: Monocytes (ALC:AMC) Ratio As Prognostic Markers in Classical Hodgkin Lymphoma Patients Treated with ABVD Chemothearapy at a Single Center in Saudi Arabia

Ibraheem H Motabi, MRCP MD, Syed Ziauddin A. Zaidi, MBBS, FRCP, FCPS, FRCPath, FACP, Shahid Iqbal, MBBS, FCPS, MRCP, Atta Munawar Gill, MBBS, MRCPI, SBAH, Imran Khan Tailor, MBBS, MD MRCP, FRCPath, Nawal Faiez Alshehry, MD SBIM, SBAH, Assem A Elghazaly, MBBChir, MS, MRCP, SBAH, Samer Homoud S Almudaibigh, MD SBIM, SBAH, Mubarak S. AlGhamdi, MD, Ghulam Murtaza, MBBS, FCPS, Ahmed Butt, MBBS

Blood (2015) 126 (23): 5004.

https://doi.org/10.1182/blood.V126.23.5004.5004

Published: 2015

Journal Articles

Evaluation of Absolute Lymphocytes: Absolute Monocytes (ALC:AMC) Ratio As Prognostic Marker in Classical Hodgkin Lymphoma Patients Treated with ABVD Chemotherapy at a Single Center in Saudi Arabia

Syed Ziauddin A. Zaidi, MBBS, FRCP, FCPS, FRCPath, FACP, Ibraheem H Motabi, MRCP MD, Shahid Iqbal, MBBS, FCPS, MRCP, Atta Munawar Gill, MBBS, MRCPI, SBAH, Imran Khan Tailor, MBBS, MD MRCP, FRCPath, Nawal Faiez Alshehry, MD SBIM, SBAH, Assem A Elghazaly, MBBChir, MS, MRCP, SBAH, Samer Homoud S Almudaibigh, MD SBIM, SBAH, Mubarak S. AlGhamdi, MD, Ghulam Murtaza, MBBS, FCPS, Ahmed Butt, MBBS

Blood (2015) 126 (23): 5005.

https://doi.org/10.1182/blood.V126.23.5005.5005

Published: 2015

Journal Articles

Outcomes and Management of Red Blood Cell Transfusions in Multiple Myeloma Patients Treated with Daratumumab

Blood (2015) 126 (23): 3571.

https://doi.org/10.1182/blood.V126.23.3571.3571

Published: 2015

Journal Articles

Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective

Xu Steven Xu, Xiaoyu Yan, Thomas Puchalski, Sagar Lonial, MD, Henk M. Lokhorst, Peter M. Voorhees, MD, Kevin Liu, Imran Khan, Richard Jansson, Tahamtan Ahmadi, Juan Jose Perez Ruixo, Honghui Zhou, Pamela L Clemens

Blood (2015) 126 (23): 4254.

https://doi.org/10.1182/blood.V126.23.4254.4254

Published: 2015

Journal Articles

Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis

Xiaoyu Yan, Pamela L Clemens, Thomas Puchalski, Sagar Lonial, MD, Henk M. Lokhorst, Robert Z. Orlowski, MD PhD, Nedjad Losic, Imran Khan, Richard Jansson, Tahamtan Ahmadi, Kristen Lantz, Juan Jose Perez Ruixo, Honghui Zhou, Xu Steven Xu

Blood (2015) 126 (23): 4222.

https://doi.org/10.1182/blood.V126.23.4222.4222

Published: 2015

Journal Articles

Management of Infusion-Related Reactions Following Daratumumab Monotherapy in Patients with at Least 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma (MM): 54767414MMY2002 (Sirius)

Peter M. Voorhees, Brendan Weiss, Saad Usmani, Huaibao Feng, Clarissa Uhlar, Imran Khan, Tahamtan Ahmadi, Sagar Lonial, MD

Blood (2015) 126 (23): 1829.

https://doi.org/10.1182/blood.V126.23.1829.1829

Published: 2015

Journal Articles

Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma

Saad Usmani, Brendan Weiss, Nizar J Bahlis, MD, Andrew Belch, Sagar Lonial, MD, Henk Lokhorst, Peter M. Voorhees, MD, Paul G. Richardson, A Kate Sasser, Amy Axel, Huaibao Feng, Clarissa Uhlar, Jianping Wang, Imran Khan, Tahamtan Ahmadi, Hareth Nahi

Blood (2015) 126 (23): 29.

https://doi.org/10.1182/blood.V126.23.29.29

Published: 2015

Journal Articles

Re-Challenging with Anti-CD38 Monotherapy in Triple-Refractory Multiple Myeloma Patients Is a Feasible and Safe Approach

Johan Lund, MD, Evren Alici, MD PhD, Michael Chrobok, MD, Astrid Gruber, MD PhD, Tahamtan Ahmadi, Imran Khan, Hareth Nahi

Blood (2015) 126 (23): 5366.

https://doi.org/10.1182/blood.V126.23.5366.5366

Published: 2015

Journal Articles

Durable Remissions in Acquired Hemophilia Patients with Inhibitor-Titer-Based Tailoring of Treatment Strategy Optimizing Rituximab Usuage – a Case Series from Single Institution in Saudi Arabia

Syed Ziauddin A. Zaidi, MBBS, FRCP, FCPS, FRCPath, FACP, Shahid Iqbal, MBBS, FCPS, MRCP (London), Imran Khan Tailor, MBBS, MD MRCP, FRCPath, Ibraheem H Motabi, MD, Nawal F Al-Shehry, MBBS, SBIM, SBAH, Assem Abdelkhalik Elghazaly, MBBChir, MS, MRCP, SBAH, Samer Al-Mudaibigh, MBBS, SBIM, SBAH, AbdulRehman Z Zaidi, MBBS Student, Abdulaziz Al-Humaidi, MBBS, SBIM, FRCPC

Blood (2014) 124 (21): 5058.

https://doi.org/10.1182/blood.V124.21.5058.5058

Published: 2014

Journal Articles

A Phase 1 Study Of JNJ-40346527, a Colony Stimulating Factor-1 Receptor (CSF-1R) Inhibitor, In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Bastian von Tresckow, MD, Franck Morschhauser, MD, PhD, Vincent Ribrag, Max S. Topp, MD, Caly Chien, PhD, Shobha Seetharam, PhD, Regina Aquino, BS, Sonja Kotoulek, BS, Imran Khan, MD, PhD, Carla de Boer, PhD, Andreas Engert, MD

Blood (2013) 122 (21): 1812.

https://doi.org/10.1182/blood.V122.21.1812.1812

Published: 2013

Journal Articles

A Novel PF4-Heparin Microbead Assay and Plasma Protein Biomarker Profiling for Improved Diagnosis of Heparin Induced Thrombocytopenia.

Resmi Ravindran, PhD, Imran Khan, Ph.D., Robert Gosselin, Ted Wun, M.D, V.V. Krishnan, Ph.D., Paul Luciw, Ph.D., Kim Janatpour, M.D

Blood (2007) 110 (11): 3216.

https://doi.org/10.1182/blood.V110.11.3216.3216

Published: 2007

Journal Articles

Multiplex Assay for Profiling Plasma Protein Biomarkers for Improved Diagnosis and Prognosis of Heparin Induced Thrombocytopenia (HIT).

Resmi Ravindran, PhD, Imran Khan, PhD, Robert C. Gosselin, Ted Wun, MD, Krish Krishnan, PhD, Paul Luciw, PhD, Kim A. Janatpour, MD

Blood (2006) 108 (11): 4106.

https://doi.org/10.1182/blood.V108.11.4106.4106

Published: 2006

NARROW

Efficacy and Safety of Viral Vector Based Gene Therapy in Patients with Hemophilia a: A Systematic Review

Efficacy and Safety of IDH Inhibitors in AML: A Systematic Review of Clinical Trials

Non-Hodgkin Lymphoma Mortality in the Elderly Population By Race, Gender, and Region in the United States

Role of Serial Positron Emission Tomography (PET) Scans in Indolent Lymphomas' Management - Interim Results from an Ongoing Prospective Study at King Fahd Medical City, Riyadh, Saudi Arabia

Phase 2 Study of 5 Days Azacytidine Priming Prior to Fludarabine, Cytarabine and G-CSF Combination for Patients with Relapsed or Refractory AML

Prognostic Stratification of Acute Myeloid Leukemia and Mylodysplastic Syndrome Patients on the Basis of Genetic Variations

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Outcome of Elderly Patients with Hodgkin's Disease-Single Centre Experience from Riyadh, Saudi Arabia

Correlation of PET Scan Negativity and Higher Absolute Lymphocytes: Monocytes (ALC:AMC) Ratio As Prognostic Markers in Classical Hodgkin Lymphoma Patients Treated with ABVD Chemothearapy at a Single Center in Saudi Arabia

Evaluation of Absolute Lymphocytes: Absolute Monocytes (ALC:AMC) Ratio As Prognostic Marker in Classical Hodgkin Lymphoma Patients Treated with ABVD Chemotherapy at a Single Center in Saudi Arabia

Outcomes and Management of Red Blood Cell Transfusions in Multiple Myeloma Patients Treated with Daratumumab

Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective

Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis

Management of Infusion-Related Reactions Following Daratumumab Monotherapy in Patients with at Least 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma (MM): 54767414MMY2002 (Sirius)

Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma

Re-Challenging with Anti-CD38 Monotherapy in Triple-Refractory Multiple Myeloma Patients Is a Feasible and Safe Approach

Durable Remissions in Acquired Hemophilia Patients with Inhibitor-Titer-Based Tailoring of Treatment Strategy Optimizing Rituximab Usuage – a Case Series from Single Institution in Saudi Arabia

A Phase 1 Study Of JNJ-40346527, a Colony Stimulating Factor-1 Receptor (CSF-1R) Inhibitor, In Patients With Relapsed Or Refractory Hodgkin Lymphoma

A Novel PF4-Heparin Microbead Assay and Plasma Protein Biomarker Profiling for Improved Diagnosis of Heparin Induced Thrombocytopenia.

Multiplex Assay for Profiling Plasma Protein Biomarkers for Improved Diagnosis and Prognosis of Heparin Induced Thrombocytopenia (HIT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only